Podcasts about mdr1

Broadcast from KSQD, Santa Cruz on 6-25-2026: Dr. Dawn devotes the show's opening to ivermectin for COVID. She walks through critical thinking principles—considering the source, cross-verification, and recognizing self-interested claims—before reviewing the evidence. The most-cited 2021 Bulgarian study of 300 people showing 77% reduction lacked accessible methods, and larger trials capable of detecting even small benefits failed to confirm efficacy. On safety, the standard 12mg parasitic dose every few weeks is well-tolerated due to the blood-brain barrier and efflux pumps that keep ivermectin out of the brain, but daily long-term dosing has caused encephalopathy, liver and kidney damage, and birth defects. Critical drug interactions—macrolide antibiotics, verapamil, proton pump inhibitors, and beta blockers—disable the efflux mechanism, and high-fat meals increase absorption 2.5-fold. Dr. Dawn shares two inflammation formulas calculable from any CBC. The Systemic Inflammatory Index (neutrophils × platelets ÷ lymphocytes) flags runaway inflammation: 200-500 is good, above 900 warrants investigation and correlates with worse stroke outcomes and rising tumor burden. The SIRI (neutrophils x monocytes ÷ lymphocytes) detects chronic tissue inflammation and early innate immune activation: below 500 is good, above 1500 indicates trouble and correlates with cardiovascular mortality and arterial plaque from M1 macrophage activity. Dr. Dawn shares two takeaways from the Institute for Functional Medicine annual conference: in patients at high cardiovascular risk by cholesterol, each gram daily of combined EPA/DHA produces a 9% risk reduction, with bruising as the dose-limit signal. Additionally, a 15-minute walk within 30 minutes of a meal nearly eliminates postprandial inflammation. An emailer asks whether an endocrinologist's claim that vitamin D leaches calcium from bones is true. Dr. Dawn confirms that very high vitamin D (above 150 nanograms, with concern starting above 90) elevates 1,25-vitamin D, which stimulates osteoclast formation and increases C-telopeptide markers of bone breakdown. A crowdsourced question asks how histamines work in women. Dr. Dawn explains histamine functions as a CNS neurotransmitter promoting alertness, wakefulness, and pain perception (deficient in narcolepsy), and as a GI signal driving acid secretion, motility, and visceral sensation. Gut bacteria can convert histidine to histamine, and fish left to spoil can trigger anaphylactic-like reactions from accumulated bacterial histamine. She notes stomach acid treatments Tagamet and Zantac are H2 blockers rather than the more familiar H1 antihistamines, and confirms histamine correlates with hormones but not particularly with minerals. A crowdsourced question on B vitamins for women in their mid-twenties prompts Dr. Dawn to recommend prenatal vitamins for those who might become pregnant, and B100 complex with calcium taken with a little apple cider vinegar for those on restricted diets or eating mostly fast food. Another question asks about chest versus belly breathing. Dr. Dawn explains babies demonstrate proper diaphragmatic breathing (belly protrudes on inhalation) while accessory muscle use signals fight-or-flight—or pneumonia in a non-crying infant. Chest breathing raises adrenaline; belly breathing calms it in adults. How do I stop compulsive scratching? Dr. Dawn explains neurodermatitis has its own ICD-10 code alongside compulsive nail-biting and hair-pulling, and it is diagnosed by sparing of unreachable areas like the mid-back between shoulder blades. Treatment includes nail clipping, lubricants, covering scabbed areas, and Prozac—which uniquely among antidepressants has a secondary indication for neurodermatitis. Zurich researchers combined immature human nerve cells with magnetic nanoparticles to create 6-micrometer NPC bots that can be magnetically positioned at spinal cord injury sites and then triggered by pulsatile magnetic stimulation to mature into nerve tissue. Mice with severed spinal cords regained movement and brain-muscle electrical signals by day 34 after daily 30-minute treatments. A study of 15,000 people with myalgic encephalomyelitis/chronic fatigue syndrome identified eight genetic regions distinguishing them from controls. Two relate to immune response to infection—consistent with the post-infectious onset many sufferers describe, including roughly half of long COVID patients—and others link to the nervous system and chronic pain. Dr. Dawn frames ME-CFS as an immune system stuck in the "on" position, unable to brake against an enemy that is long gone. An emailer asks about prostate biopsy approaches. Dr. Dawn explains the new transperineal biopsy (through skin between scrotum and anus) reduces post-biopsy infection from 1.5% to near zero and eliminates prophylactic antibiotics, though it requires more anesthesia and time. Cancer detection rates match the transrectal approach when both use MRI targeting, and she expects the transperineal approach to become standard.

Otherwise healthy cats with a genetic MDR1 mutation can develop severe neurologic effects after treatment…

Otherwise healthy cats with a genetic MDR1 mutation can develop severe neurologic effects after treatment with certain prescribed drugs. The mutation disrupts the function of P-glycoprotein, which normally clears harmful substances...

What if you could know—before you ever give a pill—whether your dog or cat is likely to have a bad reaction? In this episode, Dr. Alice and Janet sit down with Dr. Katrina Mealey, Associate Dean for Research at Washington State University's College of Veterinary Medicine, NIH-funded researcher, and Inventor of the Year for her groundbreaking genetic test that flags pets at risk for serious adverse drug reactions.Dr. Mealey explains the science in plain English: a natural “gatekeeper” protein called P-glycoprotein (coded by the MDR1 gene) protects the brain and body by pumping out potentially toxic compounds. When a pet carries certain MDR1 mutations, many common medications—prescription and OTC—can reach dangerous levels. We cover how the cheek-swab test works, how to get it for your pet, which breeds are most affected, why dosage matters so much, and how new vet-friendly tools help tailor safer treatments.In this episode:- MDR1 101: What P-glycoprotein does and why it's the body's drug “gatekeeper.”- Who's at risk: Collies (~75%), Australian & English Shepherds (~50%), plus surprises like Boxers, Huskies, and even the occasional Golden—plus the feline version discovered in 2015.- Real-world reactions: From anti-diarrheals and chemo agents to certain flea preventives—how problems present and what vets should watch for.- Testing made easy: Simple cheek swab or blood test; results emailed to you and your vet.- Dosing guidance: Meet MDR1Caddie (dogs) and WhisPurr (cats)—information that suggests dose adjustments based on whether a pet has one or two copies of the mutation.- Myth-busting ivermectin: Why tiny monthly heartworm doses are different from mange/cancer “DIY” dosing—and why self-medicating is dangerous.- Take-home for pet parents: Bring MDR1 status up with your vet before surgeries, chemo, dermatology meds, new preventives, or simple OTC medications like Immodium.About our guestDr. Katrina Mealey is a veterinarian, pharmacist, researcher, and author (editor of Pharmacotherapeutics for Veterinary Dispensing). Her lab identified the MDR1 mutation in dogs and later in cats, and continues to map which drugs interact with P-glycoprotein so veterinarians can treat more safely.https://vetmed.wsu.edu/our-team/wsu-profile/kmealey/Resources & links- MDR1 genetic test: Link in show notes to order a cheek-swab kit for dogs or cats.- Drug interaction updates: Ongoing lists and guidance are available via the testing program (see show notes).- Dose-adjustment information: MDR1Caddie (dogs) and WhisPurr(cats).- Talk to your veterinarian before starting, stopping, or changing any medication.--What started during the COVID-19 lockdown with one baby gorilla at the Cleveland Zoo has grown into a channel loved by animal fans around the world. I'm a one-person operation—filming, editing, narrating, and sharing the most heartfelt moments of baby gorillas, orangutans, elephants, and other zoo animals. Whether it's Jameela's emotional journey or Clementine's first steps, each video brings you closer to the animals and their stories. If you love watching real animal behavior, learning fun facts, and supporting conservation through storytelling—this is your place! Subscribe to Larry's Animal Safari on YouTube @larrysanimalsafari ---Support our sponsor for this episode Blue Buffalo by visiting bluebuffalo.com. BLUE Natural Veterinary Diet formulas offer the natural alternative in nutritional therapy. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents.---All footage is owned by SLA Video Productions.

What if you could know—before you ever give a pill—whether your dog or cat is likely to have a bad reaction? In this episode, Dr. Alice and Janet sit down with Dr. Katrina Mealey, Associate Dean for Research at Washington State University's College of Veterinary Medicine, NIH-funded researcher, and Inventor of the Year for her groundbreaking genetic test that flags pets at risk for serious adverse drug reactions.Dr. Mealey explains the science in plain English: a natural “gatekeeper” protein called P-glycoprotein (coded by the MDR1 gene) protects the brain and body by pumping out potentially toxic compounds. When a pet carries certain MDR1 mutations, many common medications—prescription and OTC—can reach dangerous levels. We cover how the cheek-swab test works, how to get it for your pet, which breeds are most affected, why dosage matters so much, and how new vet-friendly tools help tailor safer treatments.In this episode:- MDR1 101: What P-glycoprotein does and why it's the body's drug “gatekeeper.”- Who's at risk: Collies (~75%), Australian & English Shepherds (~50%), plus surprises like Boxers, Huskies, and even the occasional Golden—plus the feline version discovered in 2015.- Real-world reactions: From anti-diarrheals and chemo agents to certain flea preventives—how problems present and what vets should watch for.- Testing made easy: Simple cheek swab or blood test; results emailed to you and your vet.- Dosing guidance: Meet MDR1Caddie (dogs) and WhisPurr (cats)—information that suggests dose adjustments based on whether a pet has one or two copies of the mutation.- Myth-busting ivermectin: Why tiny monthly heartworm doses are different from mange/cancer “DIY” dosing—and why self-medicating is dangerous.- Take-home for pet parents: Bring MDR1 status up with your vet before surgeries, chemo, dermatology meds, new preventives, or simple OTC medications like Immodium.About our guestDr. Katrina Mealey is a veterinarian, pharmacist, researcher, and author (editor of Pharmacotherapeutics for Veterinary Dispensing). Her lab identified the MDR1 mutation in dogs and later in cats, and continues to map which drugs interact with P-glycoprotein so veterinarians can treat more safely.https://vetmed.wsu.edu/our-team/wsu-profile/kmealey/Resources & links- MDR1 genetic test: Link in show notes to order a cheek-swab kit for dogs or cats.- Drug interaction updates: Ongoing lists and guidance are available via the testing program (see show notes).- Dose-adjustment information: MDR1Caddie (dogs) and WhisPurr(cats).- Talk to your veterinarian before starting, stopping, or changing any medication.--What started during the COVID-19 lockdown with one baby gorilla at the Cleveland Zoo has grown into a channel loved by animal fans around the world. I'm a one-person operation—filming, editing, narrating, and sharing the most heartfelt moments of baby gorillas, orangutans, elephants, and other zoo animals. Whether it's Jameela's emotional journey or Clementine's first steps, each video brings you closer to the animals and their stories. If you love watching real animal behavior, learning fun facts, and supporting conservation through storytelling—this is your place! Subscribe to Larry's Animal Safari on YouTube @larrysanimalsafari ---Support our sponsor for this episode Blue Buffalo by visiting bluebuffalo.com. BLUE Natural Veterinary Diet formulas offer the natural alternative in nutritional therapy. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents.---All footage is owned by SLA Video Productions.

Send us a textWhen traditional dewormers fail against resistant hookworms, veterinarians may turn to emodepside as a last resort. But are all formulations created equal? Not according to recently published research.Join us as Teresa Quintana and Drs. Jeba Jesudoss Chelladurai and Stephanie Martinez reveal critical findings about bioequivalence between different emodepside formulations. Their research demonstrates that the feline topical formulation, when given orally to dogs at 3 mg/kg, produces approximately three times higher peak concentrations and 2.4-2.8 times greater systemic exposure compared to the EU canine modified-release tablet at the same dose.These findings carry significant clinical implications, particularly for dogs with MDR1 mutations lacking P-glycoprotein transport mechanisms. Without this protective system, emodepside can accumulate in the brain and cause neurotoxicity. The research team guides us through proper diagnostic confirmation of resistant hookworms, recommended treatment approaches, and crucial safety considerations before turning to this last-line therapy.The conversation expands into formulation differences, bioavailability challenges, and practical clinical protocols. Teresa, Jeba, and Stephanie emphasize that clients must follow strict fasting guidelines before and after administration, as food dramatically enhances emodepside absorption and could potentially lead to toxicity with the already higher-concentration feline product.Whether you're dealing with suspected resistant hookworms in your practice or simply want to understand the science behind bioequivalence and drug safety, this episode provides essential knowledge for evidence-based clinical decision-making. This episode centers around the intersection of parasitology, pharmacology, and clinical medicine and highlights why the details matter when it comes to drug formulations and routes of administration.AJVR article: https://doi.org/10.2460/ajvr.25.01.0027INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ® ? JAVMA ® : https://avma.org/JAVMAAuthors AJVR ® : https://avma.org/AJVRAuthorsFOLLOW US:JAVMA ® : Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook Instagram: JAVMA (@avma_javma) • Instagram photos and videos Twitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ® : Facebook: American Journal of Veterinary Research - AJVR | Facebook Instagram: AJVR (@ajvroa) • Instagram photos and videos Twitter: AJVR (@AJVROA) / Twitter JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

We here at NAVAS are excited to bring you a new podcast episode for the new year! And we're starting out our season of the NAVAS podcast with engaging exploration of pharmacogenetics, a groundbreaking field that examines how the genetic makeup of an animal can influence its response to medications. Have you ever had a dog or a cat that took hours, if not days, to finally return to normal after general anesthesia? It's possible that animal had a genetic mutation that altered its metabolic function, causing profound changes in the clinical effects of anesthetic drugs. In this episode, we are joined by veterinary anesthesiologist and overall gene-ius Dr. Tania Perez Jimenez, Assistant Professor of Anesthesia at Washington State University College of Veterinary Medication and head its Pharmacogenetics Laboratory. Dr. Perez Jimenez shares her expertise on the genetic factors that impact anesthesia and pain management in dogs and cats. Together with host, Dr. Bonnie Gatson, they will discuss how genetic variations can affect drug efficacy and safety in individual animals, how you can approach anesthetic management in dog breeds that commonly manifest genetic anomalies such as MDR1 mutations, why we may need to alter the way we utilize Propofol and Alfaxalone in cats and certain dog breeds, and how we could all benefit from going to more cat shows.Explore more information discussed on this podcast at the WSU Pharmacogenetics Laboratory website.If you like what you hear, we have a couple of favors to ask of you:Become a member of NAVAS for access to more anesthesia and analgesia educational and RACE-approved CE content.Spread the word. Share our podcast on your socials or a discussion forum. That would really help us achieve our mission: Reduce mortality and morbidity in veterinary patients undergoing sedation, anesthesia, and analgesia through high-quality, peer-reviewed education.Thank you to our sponsor, Dechra - learn more about the pharmaceutical products Dechra has to offer veterinary professionals, such as Zenalpha.If you have questions about this episode or want to suggest topics for future episodes, reach out to the producers at education@mynavas.org.All opinions stated by the host and their guests are theirs alone and do not represent the thoughts or opinions of any corporation, university, or other business or governmental entity.

We do everything to help our feline friends, so it's heartbreaking when a medication…

We do everything to help our feline friends, so it's heartbreaking when a medication that's meant to help ends up being life-threatening. Ingredients like eprinomectin [epp-rin-oh-MEC-tin], ivermectin [eye-ver-MEC-tin], selamectin [sell-ah-MEC-tin]...

1976: Schwedens König Carl Gustav heiratet die deutsche Silvia Sommerlath und Pussycat feiern mit "Mississippi" ihren größten Hit.

贊助我們做更好的內容：https://pay.firstory.me/user/ck4fgb04n698h0804wzdkaycj

MDR1 Defekt by Leine ab und leben

Iscriviti alla pagina Facebook► https://www.facebook.com/laboratoriolavallonea/Visita il Blog► http://www.mylav.net/

Background: Prolactinomas are the most frequent pituitary adenomas. The treatment with cabergoline, the most common dopamine agonist used, is associated with side effects such as nausea, vomiting, dizziness, headaches, movement disorders and fatigue. There is some additional evidence from case reports and small studies that some patients report neuropsychiatric side effects such as depression, gambling, hypersexuality and impulsive control disorders. Objective: In this cross-sectional study we sought to investigate the baseline clinical, demographic and disease characteristics of our patient group as well as life-time comorbidities. Additionally, side effects under treatment with cabergoline (prevalence and enhancement) and whether genetic variants of the ABCB1 gene (coding MDR1 or P-gp) could account for difference in the central neuropsychiatric side effects were investigated. Methods: Questionnaires evaluating medical history, therapy side effects and further demographic characteristics were sent to all prolactinoma patients currently treated at the Max Planck Institute of Psychiatry in Munich. Additionally, DNA extracted either from blood or saliva samples was genotyped for each patient. Results: The clinical study included a total of 92 patients (23 male and 69 female, macro-to-microadenoma-ratio 1:1). The mean age of our group at the time of the study was 49,2 ± 13,8 years. Of the 79 patients treated with cabergoline, the following side effects associated with treatment were more prominent: fatigue (n=35), headaches (n=26), depressed mood (n=26), sleep disorders (n=26), dizziness (n=22), aggressiveness (n=17), anxiety (n=19) and weight loss (n=16). 18 patients reported of decreased and 16 of increased libido. Significant effects were observed for the C-carriers and heterozygous CT-individuals of rs1045642 that presented less frequent fatigue and sleep disorders under cabergoline. In the analysis of SNP rs2032582, G-carriers seemed to be protected from enhancement of dizziness under cabergoline. SNPs rs2235015 and rs2032583 were found to have no association with the examined symptoms. Conclusion: In our group we described an increased prevalence of symptoms such as fatigue and weight loss under cabergoline, as well as neuropsychiatric side effects such as depressed mood, aggressiveness and anxiety in comparison to the available data of the literature. We demonstrated that polymorphisms of SNPs rs1045642 and rs2032582 of the ABCB1 gene predispose for fatigue, sleep disorders and dizziness under cabergoline. This is the first study demonstrating that individual ABCB1 gene polymorphisms could account for a different occurrence or enhancement of central side effects of this systematically administered medication.

Beim MDR1 Defekt entwickeln Tiere eine Über-Empfindlichkeit gegen bestimmte Medikamente. Ursache ist ein fehlerhaftes Gen. Mehr zu MDR1 im Podcast.

In gene therapy, a clinically relevant therapeutic effect requires long-term expression of the desired gene at a level sufficient to correct or at least alleviate the underlying gene defect. One approach to achieve persistent as well as high-level transgene expression in a significant percentage of target cells would be to select cells expressing both the desired transgene and a linked selectable gene such as the human multi-drug resistance (MDR1) gene-in a bicistronic vector. Because of its accessibility, the skin is a very attractive target tissue to select genetically modified cells, allowing topical application of a selecting agent, thus minimizing potential toxic side effects. Among the potential selecting drugs, agents that block cell division, such as colchicine, are of particular interest because the use of anti-mitotic drugs takes advantage of the rapid keratinocyte ( KC) turnover in the epidermis and the need for continued proliferation to substitute the KC lost due to selection. Before assessing the therapeutic benefit of such an approach, several key questions need to be answered in preclinical models: ( 1) Does topical colchicine application achieve the desired in vivo effect by blocking KC mitosis without eliciting unwanted toxic side effects? ( 2) Are MDR-transduced (MDR+) human KC still able to proliferate and differentiate when treated with colchicine? ( 3) Can MDR+ KC be enriched by topical selection? ( 4) Does topical selection result in persistent transgene expression by selecting KC stem cells expressing MDR? To answer these questions and to test the feasibility of such an approach both an in vitro skin equivalent and an in vivo human skin graft model were developed in which MDR+ KC were treated with different dosages of colchicine. Quantitative and qualitative analyses of MDR expression in human KC showed that topical colchicine treatment selects high-level transgene expression in a high percentage of KC. Moreover, determination of transgene copy numbers demonstrated that MDR+ KC progenitor cells were enriched by topical selection resulting in long-term expression of the transgene in the skin. Thus, in summary, these models demonstrate that topical selection of MDR+ KC is a safe approach to efficiently enhance long-term gene expression in the skin and holds future promise for clinical gene therapy applications. Copyright (C) 2004 S. Karger AG, Basel.